What's Driving the Recent Buzz Around AdaptHealth (AHCO)

Key Takeaways

• One Equity Partners (OEP VII GP), a significant 10% owner of AdaptHealth (AHCO), has demonstrated strong conviction by accumulating over $24 million worth of shares through multiple open-market purchases in March 2026.
• This substantial insider buying signals a belief in AHCO's long-term value, despite recent mixed financial results and a significant Q4 2025 GAAP loss.
• AdaptHealth's strategic shift towards a large-scale capitated contract and record patient census in key health segments are seen as major catalysts for future growth, potentially offsetting near-term operational investments.

What's Driving the Recent Buzz Around AdaptHealth (AHCO)?

AdaptHealth Corp. (NASDAQ: AHCO) has been making waves in the market, not just for its volatile stock performance, but for a series of highly significant insider purchases that have caught the attention of savvy investors. In March 2026 alone, One Equity Partners (OEP VII GP), a substantial 10% owner, poured over $24 million into AHCO shares through five distinct open-market transactions. This isn't just a casual top-up; it's a powerful signal from an entity with deep insights into the company's operations and future prospects.

The purchases occurred between March 10th and March 20th, with share prices ranging from $9.73 to $9.94. Specifically, OEP VII GP acquired 820,528 shares for $7,982,671 on March 10th, followed by 536,827 shares for $5,222,307 on March 11th, and another 689,336 shares for $6,707,170 on March 12th. Further buys included 727 shares for $7,228 on March 19th and 447,100 shares for $4,431,700 on March 20th. These transactions collectively represent a massive vote of confidence, especially considering the company’s recent earnings report which presented a mixed bag of results.

Such aggressive accumulation by a major shareholder often precedes significant shifts in a company's trajectory. When an insider, particularly one with a 10% stake and a history of strategic investments like One Equity Partners, commits tens of millions of dollars of their own capital, it suggests they perceive a substantial disconnect between the current market valuation and the company's intrinsic value. This conviction is particularly noteworthy given AHCO's current trading price of $11.29, which is near its 52-week high of $11.56, indicating that OEP sees further upside even after recent price appreciation.

The market has certainly reacted. AdaptHealth stock jumped 9% on March 13th following the initial disclosure of these purchases, underscoring the weight investors place on insider activity. This isn't merely speculative trading; it's a calculated move by an informed player, hinting at underlying strengths or upcoming catalysts that the broader market might not yet fully appreciate. The question for investors now is: what exactly does OEP see in AdaptHealth that warrants such a significant bet?

Why is One Equity Partners Doubling Down on AdaptHealth?

One Equity Partners (OEP) isn't new to AdaptHealth; they completed a $190 million investment in the company back in July 2020, specifically to support strategic acquisitions aimed at broadening AdaptHealth's suite of high-value health products and in-home services for chronic care patients. Their continued accumulation of shares in March 2026, totaling over 2.9 million shares acquired in Q1 2026, suggests a reinforcement of their long-term thesis, rather than a new speculative play. This deep, historical involvement provides OEP with an intimate understanding of AdaptHealth's operational nuances, strategic direction, and market positioning.

OEP's investment philosophy centers on building market-leading companies through transformative business combinations, particularly in the healthcare sector. Their prior investments in healthcare service businesses like Ernest Health and Simplura Health Group underscore their expertise in this domain. This background implies that their recent purchases are not just about a temporary undervaluation, but a belief in AdaptHealth's ability to execute on its strategic vision and capitalize on the growing demand for home healthcare solutions. The firm's managing director, Brad Coppens, even joined AdaptHealth's board as part of the initial investment, further cementing OEP's operational oversight and strategic influence.

The sheer scale of the recent purchases, with OEP VII GP now holding nearly 15.9 million shares, translates to a significant portion of the company and a substantial financial commitment. This isn't a small fund manager making a minor adjustment; it's a major shareholder actively increasing its stake by millions of shares. Such a move indicates that OEP believes AdaptHealth is either significantly undervalued relative to its future potential or is on the cusp of realizing substantial growth from its strategic initiatives. It's a clear signal that the "smart money" sees a compelling opportunity here.

This sustained conviction from a sophisticated private equity firm like OEP suggests they are looking beyond short-term market fluctuations and focusing on the long-term value creation. They likely have a detailed understanding of AdaptHealth's operational improvements, its market expansion strategies, and the potential impact of its new capitated contract, which management has called the largest service transition in the home medical equipment industry's history. For retail investors, such insider activity serves as a powerful indicator, suggesting that there's more to AdaptHealth's story than meets the eye.

AdaptHealth's Mixed Financial Performance: A Closer Look

While insider buying provides a strong bullish signal, it's crucial to contextualize it with AdaptHealth's recent financial performance, which has been a mixed bag. The company's fourth-quarter and full-year 2025 results, announced on February 24, 2026, revealed both areas of strength and significant challenges that led to a 16.4% stock drop post-earnings. This volatility highlights the divergent views on AHCO's current state and future trajectory.

On the positive side, AdaptHealth reported fourth-quarter 2025 net revenue of $846.3 million, which actually beat analyst estimates of $832.51 million. Full-year 2025 net revenue was $3.24 billion, a slight decrease of 0.5% from $3.26 billion in 2024, but organic revenue growth remained positive at 1.7% for both the quarter and the full year. Furthermore, the company achieved record patient census in Sleep Health, Respiratory Health, and Wellness at Home, alongside a patient retention record for Diabetes Health. These operational achievements underscore the underlying demand for AdaptHealth's services and its ability to attract and retain patients.

However, the bottom line was indeed "ugly," as one analyst put it. AdaptHealth posted a GAAP net loss of $102.8 million for Q4 2025, translating to a loss of $0.76 per share. This starkly missed analyst expectations for a $0.35 profit and reversed the $0.37 profit per share reported in Q4 2024. The full-year 2025 net loss was $70.8 million, a significant swing from a net income of $90.4 million in 2024. A major contributor to this loss was a non-cash goodwill impairment charge of $128.0 million in Q4 2025.

Operating margins also contracted sharply, swinging from a positive 11.4% in Q4 2024 to a negative 8.7% in Q4 2025. Adjusted EBITDA for Q4 2025 came in at $163.1 million, missing forecasts by over 14% and representing an 18.7% decrease from $200.6 million in Q4 2024. Full-year Adjusted EBITDA also decreased by 10.5% to $616.7 million. While the company generated strong cash flow from operations of $601.8 million for the full year and reduced debt by $250 million in 2025, the profitability challenges and goodwill impairment clearly spooked the market, creating the very dip that One Equity Partners capitalized on.

The Capitated Contract: A Game Changer for 2026 and Beyond?

Despite the recent earnings disappointment, AdaptHealth's management and, seemingly, One Equity Partners, are keenly focused on a major strategic initiative: a new, large-scale capitated contract. This agreement is not just another deal; management has boldly described it as the "largest service transition in the history of the home medical equipment industry." This statement alone highlights the transformative potential and the significant operational undertaking it represents for the company.

The capitated contract is expected to generate over $1 billion in locked-in revenue, providing a substantial and predictable revenue stream for AdaptHealth. This type of contract, where a healthcare provider receives a fixed payment per patient regardless of the services rendered, shifts risk but also offers significant upside for efficient providers. For AdaptHealth, it means a stable base of revenue that can fuel long-term growth and potentially smooth out the volatility often seen in traditional fee-for-service models. The company has already made significant investments in critical infrastructure and nearly 500 dedicated employees to secure the initial start dates of this agreement, including acquiring a leading HME provider in Hawaii to expand its geographic footprint to its 48th state to support this contract.

Management anticipates revenue from this contract to ramp up throughout 2026, contributing an estimated 5% to 6% of total growth for the year. This growth catalyst is a key reason why CEO Suzanne Foster stated that "2025 was a tremendous year of transition in which we made significant strides toward building a stronger operational and financial foundation," positioning the company for "strong financial performance in 2026 and beyond." The strategic investments made in 2025, including digital patient engagement and expanded self-service capabilities, doubling myApp users to 327,300, are all geared towards supporting this massive transition and enhancing operational efficiency.

However, this transition isn't without its near-term costs. The infrastructure investments required to support such a large-scale deal are expected to sharply increase operating expenses and capital expenditures through 2026. This could suppress free cash flow and pressure net margins in the short term, as evidenced by the Q4 2025 results. The challenge for AdaptHealth will be to execute flawlessly on this contract, ensuring that the long-term benefits of stable, high-volume revenue outweigh the initial investment hurdles. If execution stays on track, this capitated contract could indeed be the defining factor that reshapes AdaptHealth's financial profile and justifies OEP's aggressive buying.

Valuation Perspectives and Analyst Sentiment: A Tale of Two Models

The market's perception of AdaptHealth's valuation is currently split, presenting a fascinating "tale of two models" for investors. On one hand, the stock has seen significant momentum, with a 13.0% return over the last 7 days and a 20.0% return over the last 30 days, trading at $11.29 as of March 30, 2026. However, its 5-year total shareholder return of 69.8% remains weak, suggesting longer-term momentum has faded, leading to conflicting fair value views.

One popular narrative, often driven by traditional earnings and revenue compounding models, suggests AdaptHealth is currently overvalued. This view pegs the company's fair value at around $9.50, implying it's 17.9% overvalued at its current price. This perspective heavily weighs the near-term headwinds, such as increased operating expenses and capital expenditures associated with the new capitated contract, which are expected to suppress free cash flow and pressure net margins through 2026. Analysts following this narrative might also apply a future earnings multiple that sits below broader healthcare levels, reflecting perceived risks or slower growth.

Conversely, a discounted cash flow (DCF) model offers a dramatically different picture, estimating AdaptHealth's future cash flow value at $35.40. This perspective suggests the shares are trading approximately 68% below their intrinsic value, raising a very different question about what risks the market is currently pricing in. This DCF view likely places a greater emphasis on the long-term, stable revenue stream from the capitated contract and the company's ability to generate substantial free cash flow once the initial investment phase subsides. It also considers the company's strong cash flow from operations, which was $601.8 million in 2025, and its debt reduction efforts, with $250 million paid down in 2025, leading to credit upgrades from S&P and Moody’s.

Analyst sentiment generally leans towards a "Moderate Buy" rating, with an average 12-month price target of $13.25 from six analysts. Four analysts rate it a "buy," one a "hold," and one a "sell." Recent adjustments include Leerink Partners reducing their price objective from $13.00 to $12.00 while maintaining an "outperform" rating, and Royal Bank of Canada reaffirming an "outperform" with a $13.00 target. However, some firms like Wall Street Zen and Weiss Ratings have downgraded their stance to "hold" or "sell," reflecting the ongoing debate about the company's short-term profitability versus its long-term growth potential. This divergence in valuation and analyst opinion underscores the complexity of assessing AHCO, making the insider buying by OEP even more impactful as a potential tie-breaker.

What Does This Mean for Investors? Risks and Opportunities Ahead

For investors considering AdaptHealth, the current landscape presents both compelling opportunities and notable risks. The aggressive insider buying by One Equity Partners is a strong bullish signal, suggesting that a well-informed, significant shareholder sees substantial upside potential that the broader market might be overlooking. This conviction is likely tied to the long-term benefits of the new capitated contract, which promises stable, recurring revenue and positions AdaptHealth as a leader in the growing home healthcare market.

However, the path forward is not without its challenges. The company's recent Q4 2025 financial results highlighted significant profitability pressures, including a GAAP loss of $0.76 per share and contracting operating margins, partly due to a $128.0 million goodwill impairment charge and strategic investments in the capitated contract. These investments, while crucial for future growth, will continue to impact operating expenses and capital expenditures through 2026, potentially suppressing free cash flow and net margins in the near term. Investors must be prepared for continued volatility as AdaptHealth navigates this transition.

The home healthcare industry itself is a secular growth story, driven by an aging population and a shift towards more cost-effective, patient-centered care outside of traditional hospital settings. AdaptHealth, with its comprehensive suite of home medical equipment and services, is well-positioned to capitalize on these macro trends. The success of the capitated contract will be paramount, and its execution will dictate whether AdaptHealth can translate its strategic vision into sustained profitability and shareholder value.

Ultimately, AdaptHealth appears to be a company in transition, undergoing significant operational changes to secure long-term growth. The insider buying by OEP provides a powerful endorsement of this strategy, but investors should carefully weigh the short-term financial headwinds against the potential for substantial long-term gains. Monitoring the ramp-up of the capitated contract, management's ability to control costs, and improvements in profitability metrics will be key to assessing AHCO's trajectory in 2026 and beyond.

AdaptHealth is at a pivotal juncture, with a major insider betting big on its future. While near-term financials show strain from strategic investments, the long-term promise of its capitated contract and a growing home healthcare market could unlock significant value. Investors should watch for execution on the new contract and signs of improving profitability to confirm the insider's conviction.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.